3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'
November 11, 2016 at 10:30 AM EST
Leerink's Joseph Schwartz felt it prudent to take a deep dive into Sarepta Therapeutics Inc's (NASDAQ: SRPT) EXONDYS 51, the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.